Meeting
2018 ASCO Annual Meeting
A phase I study of 177Lu-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).
Authors
Megan Crumbaker
The Kinghorn Cancer Centre, St. Vincent's Hospital, Darlinghurst, Australia
Megan Crumbaker , Anthony M. Joshua , Richard Epstein , Louise Emmett
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS5088)
DOI
10.1200/JCO.2018.36.15_suppl.TPS5088
Abstract #
TPS5088
Poster Bd #
314a
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Michael J. Morris
Poster
2016 ASCO Annual Meeting
Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Michael J. Morris
Poster
2014 Genitourinary Cancers Symposium
A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Fatima H. Karzai
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Teresa Alonso Gordoa